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Metastatic renal cell carcinoma patients present with a 5-year
survival of less than 10%. With little or no efficacy of conven-
tional treatment strategies, including single agent chemotherapy
and hormonal therapy, new approaches are needed (Patel and
Lavengood, 1978; Krown, 1985; Maldazys and deKernion, 1986).
Previously, recombinant cytokines, notably interleukin-2 (IL-2)
and interferon-α 2a (IFN-α ), have shown encouraging results
(Rosenberg et al, 1987; West et al, 1987; Figlin et al, 1992). While
intravenous bolus or constant infusion recombinant interleukin-2
produces objective responses, this modality is associated with
significant potentially life-threatening side effects and consider-
able expenses (Rosenstein et al, 1986; Lee et al, 1989). 
Immunotherapy with subcutaneous recombinant IL-2 alone or
in combination with subcutaneous recombinant IFN-α at doses far
below the maximum tolerated dose yields significant therapeutic
efficacy while reducing treatment-related toxicity (Atzpodien et al,
1990, 1991; Sleijfer et al, 1992). The concomitant use of
chemotherapeutic agents, notably 5-fluorouracil (5-FU), further
enhances the antineoplastic activity of recombinant cytokines in
renal cell carcinoma (Wadler and Schwartz, 1990; Reiter et al,
1992). 
Tamoxifen is a non-steroidal antioestrogen which is success-
fully administered in breast cancer patients (Early Breast Cancer
Trialists’ Collaborative Group, 1992). However, tamoxifen as
single-agent appeared to be hardly effective in patients with
metastatic renal cell carcinoma (Schomburg et al, 1993). 
In this study, we report on a randomized clinical trial of s.c.
IFN-α , s.c. IL-2 and i.v. 5-FU compared to single hormonal
therapy with tamoxifen in patients with progressive metastatic
renal cell cancer. 
PATIENTS AND METHODS 
Patients 
Between October 1993 and November 1994, 78 patients (Table 1)
with progressive metastatic renal cell carcinoma were entered onto
this multicentre randomized clinical trial; median follow up of
these patients is 18 months (95% CI 13–23). Pretreatment included
radical tumour nephrectomy in all patients (n = 78), palliative
surgery (n = 39), radiotherapy (n = 7), hormonal therapy (n = 2),
chemotherapy (n = 1) immunotherapy (n = 12), immuno-
chemotherapy (n = 2) and tumourvaccine (n = 11). 
Since all treatment regimens were designed to be administrated
at home, this required selection of patients with good or excellent
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Summary We conducted a prospectively randomized clinical trial to compare the efficacy and safety of subcutaneous interferon-α 2a,
subcutaneous interleukin-2 and intravenous 5-fluorouracil as home therapy against oral tamoxifen in 78 patients with progressive metastatic
renal cell carcinoma. Treatment courses consisted of interferon-α 2a 5 × 106 IU m–2, day 1 weeks 1 + 4; days 1, 3, 5 weeks 2 + 3; 10 × 106 IU
m–2, days 1, 3, 5 weeks 5–8; interleukin-2 10 × 106 IU m–2, twice daily days 3–5 weeks 1 + 4; 5 × 106 IU m–2, days 1, 3, 5 weeks 2 + 3; and 
5-fluorouracil 1000 mg m–2, day 1 weeks 5–8. The tamoxifen group received tamoxifen 80 mg twice daily over 8 weeks. Among 41 patients
treated with interleukin-2, interferon-α 2a and 5-fluorouracil there were 7 complete (17.1%) and 9 partial responders (21.9%), with an overall
objective response rate of 39.1% (95% CI, 24.2–55.5). An additional 15 patients (36.6%) were stable throughout therapy. The overall survival
was 24 months (range 5–76+). In 37 patients receiving tamoxifen no objective remissions occurred. 13 patients (35.1%) had stable disease
and 24 patients (64.9%) showed continued disease progression. The overall survival was 13 months (range 3–73+). In summary, this home-
based therapy regimen of interferon-α 2a, interleukin-2 and 5-fluorouracil demonstrated significant therapeutic efficacy in patients with
progressive renal cell carcinoma when compared to hormonal therapy. © 2001 Cancer Research Campaign http://www.bjcancer.com
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performance status. Criteria for entry into the study were: histolog-
ically confirmed metastatic renal cell carcinoma; Karnofsky
performance status > 80%; white blood cell count > 3500 µ l–1;
platelet count > 100 000 µ l–1; haematocrit > 30%; serum creatinine
< 1.25 of the upper normal limit; chronic active infection; lack of
severe cardiac or pulmonary disease; absence of brain metastases. 
The human investigations were performed after approval by a
local Human Investigations Committee and in accordance with an
assurance filed with and approved by the Department of Health
and Human Services; written informed consent was obtained from
all patients prior to entry into the study. 
Study design 
Patients were stratified according to known clinical predictors
(Elson et al, 1988; Tourani et al, 1998) to allow for equal risk
distribution in both treatment arms (Table 2, Figure 1). They were
subsequently randomized to receive IL-2 and IFN-α combined
with 5-FU (Arm A) or tamoxifen (Arm B); randomisation was
performed on a per centre basis to rule out centre-related statistical
bias. There was no statistically significant inbalance of risk factors
and risk scores when comparing both treatment arms. 
Patients were treated in an outpatient setting. The
immunochemotherapy (Arm A) consist of IFN-α , IL-2 and 5-FU.
Sc IFN-α was administrated at 5 × 106 IU m–2, day 1 week 1 + 4,
days 1, 3, 5 weeks 2 + 3; and 10 × 106 IU m–2, days 1, 3, 5 weeks
5–8. Sc IL-2 was administrated 10 × 106 IU m–2, twice daily days
3–5 weeks 1 + 4; and 5 × 106 IU m–2, days 1, 3, 5 weeks 2 + 3;
additionally, patients received iv 5-FU at 1000 mg m–2, day 1
weeks 5–8. The hormonal therapy (Arm B) consisted of 80 mg
tamoxifen twice daily. 8-week treatment cycles were repeated for
up to 3 courses unless progression of disease occurred. 
In the immunochemotherapy group (Arm A) 34% of patients
received one cycle, 43% of patients obtained 2 cycles and 23%
received 3 cycles. In the hormonal therapy group (Arm B) 72%
of patients passed through one cycle, 19% obtained 2 cycles, 6%
received 3 cycles, and 3% obtained 4 cycles. Re-evaluation of
the patients tumour status was performed between treatment
Table 1 Patient characteristics and pre-treatment 
Characteristic All patients Arm A IL-2/INF-α /5-FU Arm B tamoxifen 
Entereda 78 41 37
Sex 
Male 59 25 23
Female 19 9 9
Age (years) 
Median 57 54 64 
Range 32–78 32–72 48–78
Pre Treatment 
Tumornephrectomy 78 41 37
Palliative surgery 39 21 18
Radiotherapy 7 4 3
Hormonal therapy 2 1 1
Chemotherapy 1 1 0
Immunotherapy 12 5 7
sc IL-2 /sc INF-α 11 5 6
INF-α 10 1
Immunochemotherapy 2 2 0
sc IL-2 /sc INF-α /iv vinblastine 1 1 0
sc INF-α /iv vinblastine  1 1 0
Tumorvaccine 11 5 6
Others 2 2 0
aPatients entered between October 1993 and November 1994.
Table 2 Risk stratification models and patient risk distributiona
I Prognostic variables according to II Prognostic variables according to 
Lopez-Hanninen et al (1996) Palmer et al (1992)
  Erythrocyte sedimentation rate > 70 mm 1 h–1   ECOG performance status > 0
  Lactic dehydrogenase > 280 U l–1   more than one metastatic site
  Neutrophilic granulocytes > 6000 µ l–1   interval from diagnosis of primary tumour to 
  Hemoglobin < 10 g dl–1 treatment of metastatic disease ≤ 2 years
  extrapulmonary metastases only
  bone metastases
Individual risk was defined as Individual risk was defined as
LR low risk in patients without any of these factors LR low risk in patients with either one or none of these factors
HR high risk in patients with one or more of these factors HR high risk in patients with more than one of these factors
aThere was no statistically significant inbalance of risk factors and risk scores when comparing both treatment arms.1132 J Atzpodien et al 
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cycles. All patients were examined by means of computed
tomography. 
After the first 8 weeks of therapy patients primarily treated with
p.o. tamoxifen crossed over to immunochemotherapy upon disease
progression wherever performance status allowed further systemic
therapy. Concomitant medication was given as needed to control
adverse effects of immunochemotherapy. 
Assessment of response, survival and toxicity 
Response to therapy was evaluated according to World Health
Organization (WHO) criteria: complete response – disappearance
of all signs of disease for a minimum of 8 weeks; partial response
– 50% or more reduction in the sum of products of the greatest
perpendicular diameters of measurable lesions, no increase in
lesion size and no new lesions; stable disease – less than a partial
response with no disease progression for at least 8 weeks; progres-
sive disease – 25% or more increase in sum of products in the
longest perpendicular diameters of measurable lesions or the
development of new lesions. Duration of response was measured
from start of therapy. In case of patients with early progression,
progression-free survival was calculated at 0 months. Survival was
measured from start of therapy to date of death or to the last known
date to be alive. 
Systemic toxicity was evaluated at weekly intervals using a
grading system adapted from the WHO. 
Treatment efficacy was assessed on intent-to-treat basis. 
Statistical analysis 
The statistical end points in our analysis were (1) objective
response and (2) overall and progression-free survival of patients.
The potential response rate was assumed to be 35% (immuno-
chemotherapy) and 5% (hormonal therapy), respectively. It was
intended to find an immunochemotherapy-induced objective
response benefit over tamoxifen at 30% with a probability of 95%
(α = 0.05) and a sample power of 1-β = 0.80. The probability of
survival was plotted over time according to the method of Kaplan
and Meier. Statistical significance was assessed using the Log-rank,
Mantel–Cox and the Breslow test. The Wilcoxon test was used to
analyse differences between dependent nonparametric data. 
RESULTS 
To balance risk factors by treatment arms patients were stratified
according to risk and, subsequently, randomised within risk
adjusted groups. 78 patients were enrolled in this clinical trial and
stratified for risk. 41 patients were randomized to receive
combined immunochemotherapy and 37 patients were randomized
to receive single-agent p.o. tamoxifen. 
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Figure 1 Overall survival (Kaplan–Meier estimates) of 78 patients stratified
for risk (Palmer et al, 1992). Survival was measured from start of therapy and
tick marks represent censored patients 
78 patients risk stratified *
78 patients randomized
41 patients assigned
sc IL-2/sc INF-α /iv 5-FU
10 patients received no
further systemic therapy
due to massive
disease progression
16 patients with disease
progression switched to 
sc IL-2/sc INF-α /iv 5-FU
regimen
47 patients continued
Immunochemotherapy for up
to three 8-week cycles 
unless progression occurred
13 patients continued
hormone treatment  for up
to three 8-week cycles 
unless progression occurred
8 patients received no 
further systemic therapy
due to massive
disease progression
37 patients assigned
po tamoxifen
Pre study evaluation
8-week re-evaluation
* Initial risk stratification was performed to allow for equal risk distribution in both treatment arms
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Treatment response 
7 patients (17.1%) treated with s.c. IFN-α , s.c. IL-2 and i.v. 5-FU
achieved a complete response and 9 patients (21.9%) had a partial
remission (Table 3). The overall objective response rate was
39.1% (95% CI, 24.2–55.5). In partial responders, the median
response duration was 18 months (range 3–31), the complete
response durations ranged from 3 to 76+ months (median not
reached). Objective tumour regressions were seen in lung (14),
lymph nodes (4), liver (1), bone (1), adrenal gland (1) and peri-
toneum (1). 15 patients (36.6 %) showed disease stabilization. The
progression-free survival in this subgroup ranged from 1 to 20
months with a median of 7 months. 10 patients (24.4%) exhibited
continuous disease progression despite therapy. 
In the tamoxifen group, there was no objective response. 13
patients (35.1%) had stable disease with a median progression-free
interval of 6 months (range 2–28). 24 patients (64.9%) showed
continued progression of disease. 
Overall survival 
Overall median survival of all patients entered into the study was
18 months, whereby 17 patients continue to be alive at last follow
up. In the immunochemotherapy regimen the median survival was
24 months (range 5–76+; 95% CI 11–37), with statistical signifi-
cance (Log rank P = 0.0325) compared to the tamoxifen group
with a median survival of 13 months (range 2–73+; 95% CI 8–18)
(Figure 3). 
In low-risk patients, there was no statistically significant differ-
ence in median survival between the immunochemotherapy group
(median survival 32 months; range 5–76+; 95% CI 12–52) and the
hormonal therapy group (median survival 26 months; range
9–73+; 95% CI 12–40) (Figure 4). In contrast, high-risk patients
yielded a significantly prolonged median survival of 16 months
Table 3 Response to home therapy according to WHO criteria (intent-to-treat) 
Response 
Tumour Siteb Complete Partial Stable  Progressive   Total 
response response disease disease
sc IL-2 /sc INF-α /iv 5-FU (41 patientsa) 
Lung 5 9 14 6 34
Lymph nodes 2 2 7 4 15
Liver – 13 3 7  
Local relapse –– 23 5
Bone – 13 2 6  
Adrenal gland – 1 – 12
Other 1c – 4d 3e 8 
Total evaluable 7 9 15 10 41
(low/high risk) (5/2)  (3/2) (10/4) (1/9) (21/20)
Percent 17.1% 21.9% 36.6% 24.4% 100%
95%, 24.2%–55.5%
po Tamoxifen (37 patients*)
Lung –– 16 14 30 
Lymph nodes –– 71 1 8
Liver –– 16 7
Local relapse –– 16 7
Bone –– 18 9  
Adrenal gland –– –   ––  
Other –– 3f 2g 5 
Total evaluable –– 13 24 37
(low/high risk) (–) (–) (9/4) (6/18) (15/22)
Percent –– 35.1% 64.9% 100%
aPatients entered between October 1993 and November 1994; Response was stratified according to Palmer et al (1992). 
bPatients may have had more than 1 site. 
cPeritoneum. 
dContralateral kidney. 
ePleura (n = 2); Thoracic wall (n = 1). 
fContralateral kidney; pleura; Thoracic wall. 
gPleura; CNS.
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Figure 3 Overall survival (Kaplan–Meier estimates) of 78 patients treated
with s.c. interleukin-2, s.c. interferon-α and i.v. 5-fluorouracil or with p.o.
tamoxifen. Survival was measured from start of therapy and tick marks
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(range 6–70+; 95% CI 12–20) after immunochemotherapy
compared to a median survival of 10 months (range 2–54+; 95%
CI 7–13) after tamoxifen therapy (Figure 5). 
Of 37 patients primarily treated with tamoxifen, 16 with
continued progressive disease crossed over to immuno-
chemotherapy regimen and showed an improved median survival
of 19 months (range 4–69+; 95% CI 9–29) as opposed to a median
survival of 10 months (range 2–72+; 95% CI 8–12) in patients
without crossover to secondary immunochemotherapy (Log rank P
= 0.0596). When compared to the combined immunochemotherapy
group, patients primarily treated with tamoxifen showed no statisti-
cally significant difference in overall survival after crossing over
(Log rank P = 0.5568) (Figure 6). 
Patients had a 5-year survival of 24.8% with combined
immunochemotherapy compared to 13.5% 5-year survival for single-
agent tamoxifen (Figure 3). In low-risk patients, there was no differ-
ence in 5-year survival between the immunochemotherapy (30.56%)
and the tamoxifen group (26.67%); while high-risk patients reached a
5-year survival of 17.50% (immunochemotherapy) and 4.55%
(tamoxifen therapy) (Figures 4 and 5). 
Patients primarily treated with tamoxifen and crossed over to
immunochemotherapy had a 5-year survival of 18.7% as opposed
to 9.5% 5-year survival in patients without crossover (Figure 6). 
The progression-free survival with a median of 7 months (range
0–76+; 95% CI 3–11) for all patients treated with the combination
therapy regimen was significantly prolonged (P < 0.0001)
compared to the tamoxifen-treated patient group (median 0
months, range 0–28) (Figure 7). 
Treatment toxicity 
Combined immunochemotherapy was well tolerated and was
always given in the outpatient setting. Side effects were mostly
limited to WHO grade I and II with patients experiencing flu-like
symptoms as malaise (grade I/II 78%; III 7%), chills (grade I/II
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57%; III 3%), fever (grade I/II 72%; III 2%), nausea/emesis (grade
I/II 77%), diarrhoea (grade I/II 34%; grade III 1%) dyspnoea
(grade I/II 26%; III 1%), hypotension (grade I/II 23%), mild
alopezia (grade I/II 14%) and paresthesias (grade I 9%). In all
except 3 patients, therapy was completed without modification of
dosage or change of time interval. No toxic deaths occurred. In the
tamoxifen group, WHO grade I nausea/emesis (17%) and mild
grade I thrombopenia (20%) were observed; no severe tamoxifen-
related side effects including hot flushes, deep vein thrombosis or
pulmonary embolism did occur (data not shown). 
DISCUSSION 
The use of biologic therapies has an established role in the treat-
ment of metastatic renal cell carcinoma (Atzpodien et al, 1990;
Wirth, 1991; Figlin et al, 1992; Stahl et al, 1992). However, very
few randomized controlled trials have confirmed the therapeutic
efficacy of rIL-2 based regimens in this disease. 
In the present prospectively randomized trial, we reported the
results of 78 patients with progressive metastatic renal cell carci-
noma who received (A) combined s.c. rIFN-α , s.c. rIL-2, and i.v.
5-FU or (B) p.o. tamoxifen. Tumour regressions occurred in 39%
of patients treated with the combined therapy (17% CRs and 22%
PRs). These controlled results were comparable to those of other
rIL-2-based therapy regimens in renal cell carcinoma (Sella et al,
1994; Joffe et al, 1996; Tourani et al, 1998). However, in previous
phase I/II studies employing our immunochemotherapy regimen
response rates of 39% (120 pts, Lopez-Hanninen et al, 1996), 38%
(25 pts, Hofmockel et al, 1996), 16% (55 pts, Joffe et al, 1996;
Dutcher et al, 1997) and 12% (52 pts, van Herpen et al, 2000),
respectively, were reported by 5 different groups. In modified regi-
mens, the combination of IL-2, IFN-α and 5-FU yielded response
rates of 31% (Ellerhorst et al, 1997), 20% (Tourani et al, 1998) and
8% (Negrier et al, 1998), respectively, with overlapping 95%
confidence intervals from 4% to 56%. 
The discrepancy in phase I/II results might be best explained by
at least 3 uncontrolled variables: (A) patient selection and clin-
ical/biological risk distribution; (B) variations in the rIL-2 based
regimen (e.g., reconstitution of drug, route and dose of administra-
tion, use of rIL-2 with concomitant chemotherapy); and (C)
different standards of patient care (e.g., surgery, supportive care
upon IL-2 therapy). 
After tamoxifen therapy some authors reported a low objective
response rate of 1.7% (95% CI, 0.04–9.09%) (Schomburg et al,
1993) based on spontaneous regression of metastatic renal cell
cancer. The lack of objective remissions in the present tamoxifen
group was most likely due to the small number of patients treated. 
Previous uncontrolled trials mostly focused on objective
responses with limited follow-ups and survival of around 2 years.
In the present study we, for the first time, reported the long-term
randomized outcome of IL-2-based immunochemotherapy in a
risk adjusted cohort of renal cell carcinoma patients. 
The median overall survival of 24 months in the
immunochemotherapy group was statistically superior to 13
months in the tamoxifen group. Notably, patients failing primary
tamoxifen could reach a median survival of 19 months after
crossing over to combined immunochemotherapy, and experi-
enced no significant decrease in long-term survival when
compared to the primary immunochemotherapy group. This may
be due to the fact that only patients with good or fair performance
status  – and hence possibly slower rate of progression – were
crossed over whereas those with lower performance status – and
hence more aggressive disease – did not undergo secondary
immunotherapy. 
Interestingly, survival graphs of low- and high-risk patients,
respectively, suggested that high-risk patients experience a more
pronounced survival benefit from immunochemotherapy
compared to oral tamoxifen. 
In most patients reported here, immunochemotherapy-related
toxicity was limited to WHO grades I and II, notably malaise,
fever, nausea, diarrhoea, while dose-limiting WHO III/IV side
effects occurred in no more than 10% of patients and always
normalized after termination of therapy. Overall, the s.c. route of
application reduced IL-2 toxicity when compared to i.v.-based
IL-2 regimens (Sleijfer et al, 1992); also, low therapy-related toxi-
city as observed here may have been due to adequate patient selec-
tion as required for home therapy. In summary, this prospectively
randomized clinical trial established the long-term therapeutic
efficacy, safety and tolerability of s.c. IL-2, s.c. INF-α , i.v. 5-FU as
a home therapy in prospectively controlled patients with
metastatic renal cell carcinoma. 
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